News >

Study Could Resolve Abiraterone/Docetaxel Debate in Hormone-Sensitive Prostate Cancer

Gina Columbus @ginacolumbusonc
Published: Monday, Jul 02, 2018

Andy Hahn, MD

Andy Hahn, MD
An ongoing phase III study could answer the question of whether abiraterone acetate (Zytiga) added to docetaxel is more effective for patients with metastatic hormone-sensitive prostate cancer than treating patients without the androgen receptor (AR) inhibitor.

The multicenter, multi-arm PEACE1 trial is studying the benefit of docetaxel plus androgen deprivation therapy (ADT), with or without abiraterone and prednisone, and with or without radiotherapy (NCT01957436). The study has an estimated enrollment of 1168 patients and an estimated primary completion date of October 2018.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication
x